A quiescent G0-like cell state as a barrier to eradication oral cancer stem cells
A quiescent G0-like cell state as a barrier to eradication oral cancer stem cells
批准号:
8722223
负责人:
Devraj Basu
金额:
$24.67万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-07 至 2016-06-30
关键词:
1-Phosphatidylinositol 3-KinaseAccountingAddressBehavior TherapyBiological AssayBiological ModelsCD44 geneCell FractionCell LineCell physiologyCellsCessation of lifeClinicalConsensusDataDominant-Negative MutationDrug TargetingDrug resistanceEpigenetic ProcessFutureGenetic TranscriptionGoalsGrowthHistonesHumanKDM5B geneLinkMalignant Epithelial CellMediatingModelingMolecular ProfilingOutcomePathway interactionsPatientsPharmaceutical PreparationsPhenotypePopulationPropertyProto-Oncogene Proteins c-aktPublic HealthRelative (related person)ReporterResistanceRoleSignal PathwaySignal TransductionSolid NeoplasmStem cellsSupporting CellSurvivorsSystemTestingTreatment FailureValidationVideo MicroscopyWorkXenograft procedurebasecancer cellcancer stem cellcancer therapycancer typecell typedisabilityimprovedin vivoinhibitor/antagonistmalignant mouth neoplasmmelanomamouth squamous cell carcinomaneoplastic cellnotch proteinnovelpreventpublic health relevanceself-renewalsmall hairpin RNAstem cell differentiationstem cell populationtherapeutic targettraittranslational studytumortumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Although cancer stem cells (CSCs) present an appealing therapeutic target in oral squamous cells carcinomas (OSCCs), a consensus molecular profile for such oral CSCs has not emerged. CSC eradication is further hampered by growing evidence of phenotypic plasticity in some non-CSCs allowing them to return to the CSC pool. Accurately defining oral CSCs together with mechanisms for restoring them after targeted depletion would establish a novel conceptual framework for effective OSCC therapy. Our preliminary work has isolated a drug-resistant subset of slow-cycling JARID1B-hi cells as a candidate CSC population in OSCC. JARID1B, a histone demethylase whose expression identifies CSCs by functional criteria in other cancer types, shows promise as a generalizable CSC marker based on its ability to mediate entry into a stem cell-like epigenetic state. Hyper-activation of the PI3-kinase (PI3K) pathway in JARID1B-hi cells renders them sensitive to depletion by PI3K-targeted drugs. Our working hypothesis is that a depleted JARID1B-hi CSC pool can be replenished by a population of quiescent "G0-like" cells, which have both high growth potential and drug resistance. While lacking the stem cell markers and PI3K pathway activity seen in JARID1B-hi cells, G0-like cells do show prominent Notch pathway activation, which has been linked to CSC population expansion and increased PI3K/AKT signaling. To explain these findings, our overall hypothesis is that entry of proliferative OSCC cells into a quiescent, G0-like state creates a reservoir to prevent permanent CSC depletion by providing a direct precursor to JARID1B-hi cells. To test this hypothesis, we will first test the roles of JARID1B- hi and G0-like subsets in OSCC growth using conventional CSC criteria (aim 1). We will specifically test whether JARID1B-hi cells have independent CSC functions, while tumor formation by G0-like cells may depend upon the JARID1B-hi fraction. Additional studies will define the precise role of G0-like cells in sustaining the JARID1B-hi population in OSCC (aim 2). Here we test whether Notch-mediated entry of non-CSCs into a quiescent G0-like state forms a direct precursor for JARID1B-hi cells, thus providing a reservoir for CSC repopulation. Validation of these concepts here would establish new model systems to dissect mechanisms underlying the cell state transitions that prevent durable oral CSC depletion during treatment. In doing so, our work will also facilitate translational studies to jointly target two distinct tumor cell phenotypes that cooperatively sustain OSCC growth via the Notch and PI3K pathways.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
-
批准号:10357120
-
项目类别:
-
资助金额:$26.59万
-
财政年份:2022
-
负责人:Devraj Basu
-
依托单位:
JARID1B-mediated epigenetic regulation of oncogenic signals in oral cancer
-
批准号:10190892
-
项目类别:
-
资助金额:$38.24万
-
财政年份:2018
-
负责人:Devraj Basu
-
依托单位:
Targeting mesenchymal-like cells in oral cancer to overcome cetuximab resistance
-
批准号:8354347
-
项目类别:
-
资助金额:$13.38万
-
财政年份:2012
-
负责人:Devraj Basu
-
依托单位:
Targeting mesenchymal-like cells in oral cancer to overcome cetuximab resistance
-
批准号:8729870
-
项目类别:
-
资助金额:$13.38万
-
财政年份:2012
-
负责人:Devraj Basu
-
依托单位:
Targeting mesenchymal-like cells in oral cancer to overcome cetuximab resistance
-
批准号:8525390
-
项目类别:
-
资助金额:$13.38万
-
财政年份:2012
-
负责人:Devraj Basu
-
依托单位:
Targeting mesenchymal-like cells in oral cancer to overcome cetuximab resistance
-
批准号:9114036
-
项目类别:
-
资助金额:$13.38万
-
财政年份:2012
-
负责人:Devraj Basu
-
依托单位:
海外基金